Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR- 4628

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Ma, Frank Y ^a,b   Han, Yingjie ^a,b   Nikolic Paterson, David J ^a,b   Kolkhof, Peter ^c   Tesch, Greg H ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BR 4628; COLLAGEN TYPE 1; FIBRONECTIN; GAMMA INTERFERON; MINERALOCORTICOID ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM CHANNEL; SODIUM CHANNEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BR-4628; CHROMONE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; MESSENGER RNA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GLOMERULAR DYSFUNCTION; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HOMEOSTASIS; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY FIBROSIS; MACROPHAGE; MOUSE; NEPHRITIS; NONHUMAN; OUTCOME ASSESSMENT; RENAL PROTECTION; T LYMPHOCYTE; URINARY EXCRETION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; GLOMERULUS; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; CHROMONES; DIHYDROPYRIDINES; FEMALE; GLOMERULONEPHRITIS; IMMUNOENZYME TECHNIQUES; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MACROPHAGES; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84956927810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145666     Document Type: Article

References (29)

1. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int. 2011; 79(10):1051-60. Epub 2011/03/18. ki201148 [pii] doi:10.1038/ki.2011.48 PMID: 21412221.
2. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012; 25(5):514-23. Epub 2012/01/20. ajh2011245 [pii] doi:10.1038/ajh.2011.245PMID: 22258336.
3. Zitt E, Eller K, Huber JM, Kirsch AH, Tagwerker A, Mayer G, et al. The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. Int J Clin Exp Pathol. 2011; 4(6):606-15. Epub 2011/09/10. PMID: 21904636; PubMed Central PMCID: PMC3160612.
4. Qin D, Morita H, Inui K, Tayama H, Inoue Y, Yoshimura A. Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis. J Nephrol. 2013; 26:8. Epub 2012/05/30. 9A41DC4F-7589-4A6B-B209-37E32162C0DF [pii]doi:10.5301/jn.5000125 PMID: 22641568.
5. Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol. 2014; 25(10):2231- 40. doi:10.1681/ASN.2012111094 PMID: 24700867; PubMed Central PMCID: PMC4178428.
6. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006; 147(11):5363-73. Epub 2006/08/12. en.2006-0944 [pii]doi:10.1210/en.2006-0944 PMID: 16901964.
7. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006; 17 (5):1362-72. Epub 2006/03/31. ASN.2005111196 [pii]doi:10.1681/ASN.2005111196 PMID: 16571782.
8. Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant. 2012; 27(3):906-12. Epub 2011/09/13. gfr495 [pii]doi:10.1093/ndt/gfr495 PMID: 21908416.
9. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010; 55(4):671-81. doi:10.1053/j.ajkd.2009.11.006 PMID: 20097461.
10. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One. 2011; 6(11):e26904. Epub 2011/11/11. doi:10.1371/journal.pone.0026904PONE-D-11-01034 [pii]. PMID: 22073219; PubMed Central PMCID: PMC3208556.
11. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving H-H. Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy. Diabetes Care. 2005; 28 (9):2106-12. doi:10.2337/diacare.28.9.2106 PMID: 16123474.
12. Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): A narrative review of safety profiles. Curr Hypertens Rep. 2014; 16 (2):414. doi:10.1007/s11906-013-0414-8 PMID: 24407447.
13. Schupp N, Kolkhof P, Queisser N, Gartner S, Schmid U, Kretschmer A, et al. Mineralocorticoid receptor- mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J. 2011; 25(3):968-78. doi:10.1096/fj.10-173286 PMID: 21135038.
14. Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology. 2012; 89(1-2):44-52. doi:10.1159/000335559PMID: 22302095.
15. Orena S, Maurer TS, She L, Eudy R, Bernardo V, Dash D, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Frontiers in pharmacology. 2013; 4:115. doi:10.3389/fphar.2013.00115 PMID: 24133446; PubMed Central PMCID: PMC3796291.
16. Suganami T, Mukoyama M, Sugawara A, Mori K, Nagae T, Kasahara M, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol. 2001; 12 (12):2652-63. PMID: 11729234.
17. Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94- 8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012; 7(8):1385-403. doi:10.1002/cmdc.201200081 PMID: 22791416.
18. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010; 285(39):29932-40. doi:10.1074/jbc.M110.131342 PMID: 20650892; PubMed Central PMCID: PMC2943305.
19. Tesch G, Sourris KC, Summers SA, McCarthy D, Ward MS, Borg DJ, et al. Deletion of bone-marrowderived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes. Diabetologia. 2014; 57(9):1977-85. doi:10.1007/s00125-014-3291-z PMID: 24957662.
20. Barish GD, Downes M, Alaynick WA, Yu RT, Ocampo CB, Bookout AL, et al. A Nuclear Receptor Atlas: macrophage activation. Molecular endocrinology. 2005; 19(10):2466-77. doi:10.1210/me.2004-0529PMID: 16051664.
21. Kerr PG, Nikolic-Paterson DJ, Atkins RC. Rapidly Progressive Glomerulonephritis. In: RW S, editor. Diseases of the Kidney and Urinary Tract. 8 ed. Boston, USA: Lippincott Williams and Wilkins; 2007. p. 1511-35.
22. Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone blockade in murine lupus nephritis. Arthritis research & therapy. 2008; 10(1):R5. doi:10.1186/ar2353 PMID: 18197980; PubMed Central PMCID: PMC2374470.
23. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, et al. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res. 2008; 314(20):3654-62. Epub 2008/10/22. S0014-4827(08) 00374-1 [pii]doi:10.1016/j.yexcr.2008.09.018 PMID: 18929559.
24. Lai L, Chen J, Hao CM, Lin S, Gu Y. Aldosterone promotes fibronectin production through a Smad2- dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun. 2006; 348(1):70- 5. PMID: 16876110.
25. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005; 46 (4):1039-45. Epub 2005/08/10. 01.HYP.0000174593.88899.68 [pii]doi:10.1161/01.HYP.0000174593.88899.68 PMID: 16087786.
26. Chen D, Chen Z, Park C, Centrella M, McCarthy T, Chen L, et al. Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. Gene. 2013; 531(1):23-30. doi:10.1016/j.gene.2013.08.047 PMID: 23994292.
27. Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol. 2009; 296(6):F1323-33. Epub 2009/04/03. 90428.2008 [pii] doi:10.1152/ajprenal.90428.2008 PMID: 19339632.
28. Huang LL, Nikolic-Paterson DJ, Ma FY, Tesch GH. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. Nephron Exp Nephrol. 2012; 120 (4):e115-22. doi:10.1159/000339500PMID: 22814207.
29. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63(5):1791-800. PMID: 12675855.